Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.64 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.61 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561515 | 1.00 | PRMT5 (0.64) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL561654 | 1.00 | PRMT5 (0.64) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL17359784 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL31652766 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL31652943 | 0.93 | PRMT5 (0.59) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL12170653 | 0.88 | ADORA3 (0.56) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL17445618 | 0.86 | ADORA3 (0.55) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL2318607 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL14946260 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA | |
| SCHEMBL6426564 | 0.85 | PRMT5 (0.65) | PRMT5WDR77ADORA3ADORA2API4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648054-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | ROCHE PALO ALTO LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120034184-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8071567-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-6784166-B2 | FOR THE TREATMENT OF DISEASES MEDIATED BY THE HEPATITIS C VIRUS | SYNTEX (U.S.A.) LLC | 2004-08-31 | — | — | US | disclosed |
| US-6762170-B1 | ANTIINFLAMMATORY AGENTS INHIBIT LEUKOCYTE RECRUITMENT AND ACTIVATION AND ARE AGONISTS OF THE ADENOSINE 2A RECEPTOR; PENDANT ISOXAZOLE; REACTING A 2,6-DIAMINOPURINE WITH A 2-(3-SUBSTITUTED ISOXAZOL-5-YL)TETRAHYDROFURAN-3,4-DIOL | SMITHKLINEBEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1090023-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| EP-1090022-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| EP-1051425-A2 | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999067265-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067266-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067264-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067263-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| EP-0948509-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999038877-A2 | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |
| WO-1998028319-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | PRMT5 556/4885WDR77 2042/4885ADORA3 583/4885 |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | PRMT5 556/4885WDR77 2042/4885ADORA3 583/4885 |
| US-20120034184-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | PRMT5 456/4885WDR77 1692/4885ADORA3 299/4885 |
| US-20130237491-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | PRMT5 556/4885WDR77 2042/4885ADORA3 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.